Acute renal failure in paediatric systemic lupus erythematosus: Treatment and outcome

Rheumatology

Volumn 48, Issue 2, 2009, Pages 176-182

  Benseler, S M ^a,b   Bargman, J M ^c   Feldman, B M ^a,b   Tyrrell, P N ^a   Harvey, E ^a   Hebert, D ^a   Silverman, Earl D ^a,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adolescent rheumatology; Autoimmunity; Health services and practice; Outcome measures; Renal; Rheumatic disease; Rheumatic diseases; Systematic lupus erythematosus; Tissues

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; PREDNISONE; STEROID;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; ARTICLE; CHILD; CHILD HEALTH CARE; CLINICAL PROTOCOL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIALYSIS; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; INFECTION RATE; KIDNEY FUNCTION; LABORATORY TEST; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AREA UNDER CURVE; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; KIDNEY; KIDNEY FAILURE, ACUTE; KIDNEY FUNCTION TESTS; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 58749108473     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken445     Document Type: Article

References (34)

1. Gupta KL. Lupus nephritis in children. Indian J Pediatr 1999;66:215-23.
2. Balkaran BN, Roberts LA, Ramcharan J. Systemic lupus erythematosus in Trinidadian children. Ann Trop Paediatr 2004;24:241-4.
3. Hu W, Liu Z, Shen S et al. Cyclosporine A in treatment of membranous lupus nephropathy. Chin Med J 2003;116:1827-30.
4. Huong DL, Papo T, Beaufils H et al. Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. Medicine 1999;78:148-66.
5. Mosca M, Pasquariello A, Tavoni A et al. Predictors of renal outcome in diffuse proliferative glomerulonephritis in systemic lupus erythematosus. Lupus 1997;6:371-8.
6. Sumboonnanonda A, Vongjirad A, Suntornpoch V, Laohapand T, Parichatikanond P. Renal pathology and long-term outcome in childhood SLE. J Med Assoc Thai 1998;81:830-4.
7. Wang LC, Yang YH, Lu MY, Chiang BL. Retrospective analysis of mortality and morbidity of pediatric systemic lupus erythematosus in the past two decades. J Microbiol Immunol Infect 2003;36:203-8.
8. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-50.
9. Yee CS, Gordon C, Dostal C et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 2004;63:525-9.
10. Barbano G, Gusmano R, Damasio B et al. Childhood-onset lupus nephritis: A single-center experience of pulse intravenous cyclophosphamide therapy. J Nephrol 2002;15:123-9.
11. Vachvanichsanong P, Dissaneewate P, Winn T. Intravenous cyclophosphamide for lupus nephritis in Thai children. Scand J Rheumatol 2004;33:339-42.
12. Bogdanovic R, Nikolic V, Pasic S et al. Lupus nephritis in childhood: A review of 53 patients followed at a single center. Pediatr Nephrol 2004;19:36-44.
13. Hagelberg S, Lee Y, Bargman J et al. Longterm followup of childhood lupus nephritis. J Rheumatol 2002;29:2635-42.
14. Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076-84.
15. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28.
16. Illei GG, Takada K, Parkin D et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: Long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002;46:995-1002.
17. Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000;136:243-7.
18. Rosner B, Prineas RJ, Loggie JM, Daniels SR. Blood pressure nomograms for children and adolescents, by height, sex, and age, in the United States. J Pediatr 1993;123:871-86.
19. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 1992;35:630-40.
20. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
21. Brunner HI, Silverman ED, Bombardier C, Feldman BM. European consensus lupus activity measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus. Arthritis Rheum 2003;49:335-41.
22. Vitali C, Bencivelli W, Isenberg DA et al. Disease activity in systemic lupus erythematosus: Report of the consensus study group of the European workshop for rheumatology research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European consensus study group for disease activity in SLE. Clin Exp Rheumatol 1992;10:541-7.
23. Fortin PR, Abrahamowicz M, Clarke AE et al. Do lupus disease activity measures detect clinically important change? J Rheumatol 2000;27:1421-8.
24. Gladman DD, Goldsmith CH, Urowitz MB et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000;27:373-6.
25. Gladman DD, Urowitz MB, Goldsmith CH et al. The reliability of the systemic lupus international collaborating clinics/American college of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809-13.
26. Niaudet P. Treatment of lupus nephritis in children. Pediatr Nephrol 2000;14:158-66.
27. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80.
28. Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31.
29. Font J, Cervera R, Espinosa G et al. Systemic lupus erythematosus (SLE) in childhood: Analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. Ann Rheum Dis 1998;57:456-9.
30. Bansal VK, Beto JA. Treatment of lupus nephritis: A meta-analysis of clinical trials. Am J Kidney Dis 1997;29:193-9.
31. Hullsiek KH, Louis TA. Propensity score modeling strategies for the causal analysis of observational data. Biostatistics 2002;3:179-93.
32. Newgard CD, Hedges JR, Arthur M, Mullins RJ. Advanced statistics: The propensity score-a method for estimating treatment effect in observational research. Acad Emerg Med 2004;11:953-61.
33. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81.
34. Grishman E, Gerber MA, Churg J. Patterns of renal injury in systemic lupus erythematosus: Light and immunofluorescence microscopic observations. Am J Kidney Dis 1982;2(Suppl. 1):135-41.